Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500818 | 1.00 | OPRK1 (0.39) | OPRK1BACE1MAOAMAOBCASP3 | |
| SCHEMBL4505765 | 0.93 | MAOA (0.38) | BACE1MAOAMAOBCASP3ALKBH5 | |
| SCHEMBL4505768 | 0.93 | MAOA (0.38) | BACE1MAOAMAOBCASP3ALKBH5 | |
| SCHEMBL4493143 | 0.90 | BACE1 (0.37) | BACE1MAOAMAOBCASP3BRD4 | |
| SCHEMBL4493148 | 0.90 | BACE1 (0.37) | BACE1MAOAMAOBCASP3BRD4 | |
| SCHEMBL4504089 | 0.89 | BACE1 (0.43) | BACE1MAOAMAOBCASP3BRD4 | |
| SCHEMBL4504092 | 0.89 | BACE1 (0.43) | BACE1MAOAMAOBCASP3BRD4 | |
| SCHEMBL4477010 | 0.88 | ROCK2 (0.40) | BACE1MAOAMAOBCASP3ALKBH5 | |
| SCHEMBL4477014 | 0.88 | ROCK2 (0.40) | BACE1MAOAMAOBCASP3ALKBH5 | |
| SCHEMBL228496 | 0.86 | ALDH1A1 (0.44) | BACE1MAOBCASP3KMT2ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | OPRK1 423/4885BACE1 1615/4885MAOA 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.